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Introduction 
Health systems in Europe and beyond are facing a combination of upward cost pressures and declining 
economically productive populations, with population ageing contributing to a growing burden of non- 
communicable disease and technological progress increasing the opportunities to intervene.1,2 Public 
and private expenditure on health systems in EU countries has risen from on average 7.3% of GDP in 
2000 to 9.0% in 2012, with further increases expected, increasing demands that these health systems 
demonstrate their effectiveness and cost-effectiveness.3,4 
Historically, rising expenditures associated with an ever widening range of pharmaceuticals and medical 
devices extending the range of conditions that can be treated have led to increasing use of Health 
Technology Assessment (HTA), a systematic analysis of clinical, economic, societal and other impacts of 
new technologies compared with existing alternatives.5 However, HTA has so far mainly been applied to 
technologies which are being considered for potential inclusion in a benefit package rather than looking 
at the value of continued investment in existing services. For the many existing procedures and 
technologies that make up health systems, any systematic assessment of disinvestment options can be 
associated with technical and political challenges.6,7 
The availability of health economic evidence has increased dramatically in recent years, as evidenced by 
the large number of citations in specialist health economic databases. As early as 2005, the NHS 
Economic Evaluation Database (NHS EED) and Office of Health Economics’ Health Economic Evaluations 
Database (HEED) included over 16,000 and 31,750 citations, respectively.8 However there are difficulties 
in applying evidence from these databases in practice for a range of reasons, including budgetary silos 
between departments and organiszations, and differences in the design of economic analyses according 
to the stakeholders concerned, ranging from wide societal and long-term perspectives to more concrete 
budgetary and short-term analyses .9 
One of the objectives of the Research Agenda for Health Economic Evaluation, implemented by the 
World Health Organization in partnership with the European Commission Consumer, Health, Agriculture 
and Food Executive Agency (CHAFEA), is to identify knowledge gaps where further research could 
facilitate the uptake and impact of economic evidence in practice. An expert panel of health economists 
and public health practitioners with expertise in the 10 highest burden conditions in the EU was 
assembled to discuss the available evidence, identify knowledge gaps and make recommendations for 
future methodological research in the field of health economics. 
 
 
Methods 
 
Identification of the highest burden conditions in the EU 
The 10 conditions representing the highest burden of disease in the European Union (EU) were selected 
based on Disability Adjusted Life Years (DALYs) from the Global Burden of Disease (GBD) study.10 One 
disease category identified with this approach, “Other Musculoskeletal Disorders”, was an aggregate of 
62 discrete conditions with separate International Classification of Disease (ICD) 10 codes. For the 
present analysis, the most significant single condition from the list of 62 was identified by expert 
  
 
 
 
 
opinion, and in addition the highest ranking single musculoskeletal disorder (MSD) from the main GBD 
list was also selected for inclusion. 
 
Expert panel 
Health economic experts on the study conditions were identified by an assessment of the volume of 
peer-reviewed literature by author. The analysis was carried out with PubReMiner11 using the search 
term “(cost-benefit OR cost-utility OR cost-effectiveness)” in combination with the study conditions. The 
highest ranking European authors were shortlisted and candidates of approximately equal technical 
strength were considered based on nationality and gender to improve representation. In addition, high 
level public health experts were invited to join the panel to provide links with the policy cycle and with 
preventive interventions and policies. 
 
Literature analysis 
As a framework for considering the economic evidence and identifying methodological research 
priorities, for each of the 10 conditions clinical management was stratified according to disease 
characteristics and type of treatment based on the Up-to-Date database.12 Full health economic 
evaluations and reviews of evaluations indexed by PubMed/MEDLINE 
(http://www.ncbi.nlm.nih.gov/pubmed) were identified using the Medical Subject Headings (MeSH) 
controlled vocabulary: “Cost-Benefit Analysis [N03.219.151.125]”, “Economics, Pharmaceutical 
[N03.219.390]” and “Technology Assessment, Biomedical [N03.880]” (including “Technology, High-Cost 
[N03.880.502]”), combined with MeSH terms for each of the 10 conditions. Although a more exhaustive 
approach using additional databases and free-text terms could have been adopted, the added sensitivity 
was not considered to be of primary importance to the objectives of the project. 
 
Inclusion criteria for primary studies were: full economic evaluations (cost-benefit, cost-effectiveness 
incl. cost-utility), English abstract. Reviews were included if their search strategies included full 
economic evaluations. Studies without an integrated effectiveness component (i.e. cost or economic 
burden of illness, cost of treatment, cost-consequence etc.) were excluded. A cut-off year was not 
enforced for primary studies, but only reviews from 2009 or later were included. No geographical 
limitations were imposed. All searches were conducted in July-August 2014, except for the category 
“Other Musculoskeletal Disorders” which were conducted in November 2014. A literature database was 
constructed in which all included primary studies and reviews were mapped to the relevant clinical 
management category. Narrative reviews were produced for each study condition based on the 
identified literature, using recently published reviews (2009 onwards) when available, and by consulting 
primary studies otherwise. 
 
Consultation and expert panel meeting 
The results of the narrative reviews were appraised by the expert panel and their feedback was 
incorporated. In addition, a public consultation was held from November to December 2014, during 
which 51 comments were received and incorporated. The expert panel was assembled for a 2.5 day 
meeting in Brussels, February 2015, where the results of the literature analysis were discussed to 
identify limitations of the existing evidence and methodological evidence gaps. 
  
 
 
 
 
Results 
 
High burden conditions in the EU 
According to the Global Burden of Disease study,10 the causes of the highest disease burden in the EU 
have changed little over the past two decades. Non-communicable diseases and accidental falls account 
for the top 10 causes of morbidity and mortality in 2010 (Table 1), with only neck pain entering and self- 
harm leaving the top 10 since 1990. Due to the diverse nature of the “Other Musculoskeletal” category, 
in the present work we consider osteoporosis as a prominent representative, and augment the category 
with osteoarthritis, the highest burden single musculoskeletal disorder outside the top-10, resulting in 
11 study conditions. 
A notable feature of the study conditions is the potential to co-exist in a single individual, by chance, 
because one predisposes to the other, or because they share common risk factors , such as diabetes and 
depression,13 lung cancer and cardiovascular disease or COPD,14 back pain and depression,15 stroke 
survival and falls16 and so forth. A number of common risk factors can be identified, including smoking 
(stroke,17  lung cancer,18  COPD,19  ischemic heart disease,20  low back pain21), high blood pressure 
(ischemic heart disease, 20 stroke22), and sedentary lifestyle (ischemic heart disease, 20 stroke,23 
diabetes24). Some of these disorders may appear early in the life course during economically productive 
ages, and there is an increase in multi-morbidity with increasing age.25 
Literature analysis 
The volume of published economic evaluation studies available for analysis varied significantly by 
condition, with ischemic heart disease (IHD), diabetes and stroke accounting for the largest volume of 
economic evidence with 283, 242 and 116 papers respectively included in the present mapping (Table 
2). There was no apparent correlation between burden of disease and volume of evidence, with some 
high burden conditions attracting little economic evidence compared with others (e.g. low back pain and 
depression with 65 and 61 papers, diabetes with 242 papers). 
 
Notably, in eight out of the 11 conditions examined, less than 100 studies were available per condition, 
while the number of clinical management strategies in these cases varied from 12 (osteoporosis) to 63 
(low back pain). Generally, economic evidence clustered around particular interventions accounting for 
a significant proportion of studies, such as pharmacology in depression (57% of all studies), 
bisphosphonates in osteoporosis (48%) and spinal manipulation in neck pain (60%). Consequently many 
clinical interventions were completely unstudied in the economic literature, or addressed in only a small 
number of studies (not shown). A detailed account of evidence gaps in the disease specific literature is 
provided elsewhere.26 
The narrative reviews were used as a basis for identifying cross-cutting methodological and technical 
issues common to two or more disease areas, which were considered by the expert panel to derive 
methodological research priorities. 
  
 
 
 
 
Expert panel recommendations for research 
The Expert Panel consisted of health economic specialists in the 11 study areas, as well as generalists in 
the field of health economics and public health (Table 3). The panel discussed the results of the 
literature analysis over a 2.5 day meeting in Brussels, February 2015. The deliberations of the panel 
regarding methodological and cross-cutting issues are given in the following sections, with 
recommendations for research summarized in Table 4. 
 
Determination of cost-effectiveness thresholds 
 
The applicability of the most widespread form of cost-effectiveness evaluation in Europe, yielding 
incremental cost-effectiveness ratios of study technologies against selected comparators, hinges on the 
estimation of a cost-effectiveness threshold above which a given technology is not considered cost- 
effective. Within the panel views varied as to whether there should be explicit cost-effectiveness 
thresholds expressed, for example, as cost per QALY. When explicit thresholds exist they are currently 
set arbitrarily, and little or no concern is given to which groups of patients are likely to lose out due to 
service displacement. Despite several recent attempts, there is still an urgent need to determine 
appropriate methods of estimating what cost-effectiveness thresholds should be. 
 
Personalized medicine 
 
Discussions on most disease areas highlighted how care needs to be targeted to patients that benefit 
the most, using appropriate risk scores, patient characteristics or other methods of stratification. 
Concerns were raised about personalized medicine, emphasizing the need to go beyond the ‘omics’ 
approach to include all characteristics that are relevant for stratification. This improves both clinical 
outcomes and cost-effectiveness of treatment. Discussions also highlighted the need to determine cost- 
effectiveness of current guideline recommended treatments, focusing on determining for which patients 
existing treatments are ineffective, and how patients can be guided away from such treatments on the 
pathway of care in order to free up resources for higher value care. 
 
Disinvestment from low value care 
 
Apart from leveraging insights from personalized medicine to identify and disinvest from care which is 
not (cost-)effective, it was noted that evaluations should include all relevant comparators, which is not 
always the case. Including a hypothetical “doing nothing” scenario in standard economic evaluations, 
although not usually a realistic clinical option, would allow the cost-effectiveness of existing treatments 
to be determined. Further research is needed on approaches for identifying candidate treatments for 
disinvestment. 
 
Real-world evidence 
 
The limitations of clinical trial evidence for predicting real world effectiveness are well known and 
described, due for instance to differences between strictly controlled trial populations and the wider 
patient population.27,28 Methods of generating, synthesizing and applying real-world evidence from 
pragmatic trials, registry data and similar sources should be further explored and experiences 
  
 
 
 
 
exchanged. This would allow evaluation of the cost-effectiveness of treatments in practice, as well as 
generation of parameter input for real-world model-based cost-effectiveness studies as opposed to 
trial-based studies. The acceptability of such evidence to key stakeholders, including reimbursement 
agencies as part of existing HTA processes and for the monitoring of post-launch real- world cost-
effectiveness, should be explored. 
 
Early Health Technology Assessment 
 
Cost-effectiveness research is mostly undertaken in the late stages of treatment development where 
considerable investments have already been made. Early cost-effectiveness analysis could help 
manufacturers to decide about further development of a treatment, set realistic performance-price 
goals, and design and manage a regulatory and reimbursement strategy. 
 
Measures of costs and benefits 
 
Variations in reporting practices for measurements of input resource use and costs currently constrain 
evidence transfer between settings and jurisdictions and the applicability of evidence over time. 
Including a range of expected generic prices following patent expiry as part of an economic evaluation of 
a new pharmaceutical would be a welcome addition to understanding lifecycle costs of a technology. In 
addition, economic evaluation studies should report resource use and unit costs separately to improve 
transferability and reuse of evidence. 
Estimating indirect costs due to illness in older people has largely been neglected, and best practices 
should be developed to realistically assess losses and gains associated with the roles played by those in 
this age group with respect to informal care, child care and other activities. Similarly, little attention has 
been paid to return to education in young people with health problems, which can significantly affect 
their life chances, and thus return on investment. 
Finally, applying patient reported outcome measures may be a particular challenge in certain patient 
groups, such as those receiving palliative care, recovering from stroke or other severe illnesses, where 
small functional improvements can be perceived to be very important, or where language or cognitive 
abilities are limiting factors.29 Further research is needed to understand how benefit can most 
appropriately be measured in these groups. There is a need for a broader set of health outcome 
measures that go beyond the outcomes captured by a generically defined QALY, e.g. indicators such as 
the ability to live an independent life, avoid loneliness, maintain societal status and the ability to cope. 
Such measures can be used to study the impact of interventions in the care sector as well as the cure 
sector. 
 
Standardized open-access economic models of appropriate complexity 
 
A significant body of economic evidence is focused on commercial high value products and funded by 
their manufacturers. Structural and parameter variations are known to significantly affect cost- 
effectiveness results, and can be chosen selectively to favor particular outcomes resulting in biased 
analyses. Publicly funded, validated, open-access and open-source economic models would reduce the 
  
 
 
 
 
risk of bias, provide a common platform for economic evaluations across countries, provide a reliable 
source of information for reimbursement submissions and reduce duplication of effort across countries. 
However, as recent experience with treatment for macular degeneration has shown, vested interests 
may create barriers to such studies.30 
Research in this area could also usefully establish the tradeoffs inherent in model complexity; more 
sophisticated models require more data, often to the point where requirements exceed availability, 
which introduces more uncertainty in results. It is not known whether simplified models with more 
limited evidence requirements could be reasonable approximations to their more complex counterparts. 
 
Complex care, combinations and pathways 
 
There is little evidence on the cost-effectiveness of complex health interventions such as palliative or 
integrated care, either generally or for specific conditions (for ethical reasons the role of economic 
evaluation in palliative care is mostly relevant to the choice between different models,31 rather than 
palliative care vs other interventions). Similarly, treatments which are well studied individually are often 
not studied as part of complex regimens, both in the case of multiple treatments for the same condition, 
or as simultaneous treatments for multiple, comorbid conditions. The sequence in which individual 
treatments are given along a pathway of care and cut-off points for changing therapies are often not 
well understood. 
 
Treatment programmes may also contain mixtures of pharmacological and non-pharmacological 
interventions, or interventions directed both at patients, healthcare providers and the organization of 
care, such as integrated care programs or disease management programs. There is a need for methods 
to address the cost-effectiveness of treatments given under these complex conditions. 
 
Evidence within and outside the health sector 
 
Health in all policies is promoted as a policy principle, but in many cases health benefits are not 
modelled as part of interventions with an impact on health either directly or through determinants of 
health, such as social housing and education. The economic methods used in other sectors, often cost- 
benefit or return-on-investment, are generally different from methods used within the health sector, 
mostly cost-effectiveness including cost-utility. Increased awareness of the health impacts of actions in 
other sectors, along with developments to bridge the gaps between the technical approaches of health 
and other sectors, could encourage the incorporation of health effects in wider policy evaluations. 
Effects of health interventions external to the health system are included in health economic 
evaluations in the form of productivity losses/gains, although many evaluations take a more restricted 
health system perspective in which such values are not included. 
 
 
Discussion 
The present work represents an attempt to outline broad research priorities for the field of health 
economics in the European Union, as viewed by health economics and public health experts from the 
region, representing producers and users of such evidence, respectively. This is in contrast to earlier 
  
 
 
 
 
priority setting exercises which have focused, for example, on the needs of specific HTA agencies,32 
have consulted more widely with governments, industry, academia and other stakeholders on priorities 
relevant for a particular country,33 or for a particular health condition.34 The present approach is 
intended to be relevant to the European Union broadly, and to address underlying methodological 
issues, which can be considered universal, without the additional complexity of national variations for 
example in the approach to HTA or in the organisation of health systems. It is especially relevant as the 
European Union explores ways of fostering stronger co-operation among HTA agencies.35 
 
At the core of health economic evaluation, the question of determining an appropriate cost- 
effectiveness threshold tends to receive little systematic attention, with acceptable thresholds or ranges 
largely determined by precedents and without solid justification.36–38 The underlying premise of a 
cost-effectiveness threshold, assuming some reallocation of resources is needed to fund the new 
intervention, is that a newly introduced service should provide more “health benefit” than the services 
that are foregone to release the required finance. In other words, this interpretation of a threshold 
implies that as long as total health gain is maximized, it does not matter who gains or loses. This has 
obvious implications for other health system objectives such as equity,39 and indeed there is a lack of 
attention in the literature to which services and/or patient groups tend to lose out when new services 
are adopted for reimbursement.40,41 This approach also implicitly assumes that the cost-effectiveness of 
all existing interventions is known, which is far from the case. 39 
Furthermore, if additional funding is made available in the health budget to finance new interventions, 
an estimate of the consumption value of health is required, i.e. how much of other forms of 
consumption we are willing to forgo to increase health outcomes. One (but not the only) way of 
addressing this is by estimating a societal “willingness to pay” (WTP) for health gains, although it is not 
straightforward to determine what such a WTP should be. Past decisions are unlikely to provide a good 
metric as economics are rarely the only consideration behind a decision,39 and recent work has 
demonstrated that individual WTP differs substantially between income brackets42 complicating efforts 
to obtain a societal value. Interpretation and definition of the cost-effectiveness threshold is a political 
issue, but research is lacking to support a transparent and evidence based decision. Further to this, it is 
not clear how non-economic considerations such as ethical (e.g. end of life care) or distributional 
concerns (e.g. areas with high unmet clinical need) should be integrated. In practice this has resulted in 
cost-effectiveness thresholds being ignored or extended e.g. for orphan drugs.43 Multiple Criteria 
Decision Analysis (MCDA) has been suggested as one way to integrate disparate factors44 although 
experience in practice is currently limited to experimental assessment.45 
The threshold debate is directly related to the issue of disinvestment particularly when healthcare 
budgets are fixed. Since the systematic process of Health Technology Assessment is largely concerned 
with assessing technologies for investment at a central level, the freeing of resources (disinvestment) to 
finance implementation often happens at the local level where economic considerations, i.e. the 
identification of low-value care, are often not considered. In addition the value of services may differ 
according to priorities and specific conditions between localities, and consequently central 
disinvestment (or indeed investment) advice may not be appropriate.46–48 
  
 
 
 
 
The present research recommendations therefore support the identification of substantiated cost- 
effectiveness thresholds together with efforts to estimate the cost-effectiveness of existing treatments 
according to patient characteristics, in order to improve information available for the identification of 
and potential disinvestment from low value care. Treatment effects are well known to vary by 
subgroups of patients; however in a sample of 97 clinical trials published in the New England Journal of 
Medicine between 2005 and 2006, subgroup analysis was undertaken only for 59 (61%) and results of 
these were not consistently reported.49 Though clinical trials can give important clues about subgroups 
experiencing better clinical outcomes, they are generally designed to optimize internal validity at the 
expense of generalizability.50 Examples of prospective real-world trials exist, in which investigators seek 
to determine in which patient groups an intervention is more cost-effective under everyday practice 
conditions.51 Use of pragmatic clinical trials, as well as registry-based studies, is considered a valuable 
addition to, but not a substitute for traditional explanatory trials, and will give decision-makers more 
realistic insight into the cost-effectiveness of treatments across patient subgroups in actual clinical 
practice. Real-world evidence however cannot provide evidence on pure treatment effects, and there 
are obvious risks of bias if non-randomized study designs are adopted, even though in some 
circumstances they are the only feasible option, e.g. for public health interventions implemented 
nationwide. Consequently there is a need to determine the acceptability of real-world evidence to 
decision-makers, in particular reimbursement authorities,.52 in the context of growing concern about 
initiatives such as adaptive pathways that call for their greater use as a means of expediting market 
entry.53 Notwithstanding this, with caution, real-world evidence can be an important source of data 
particularly for estimating parameters that are not subject to selection bias, and may contribute to 
understanding the cost-effectiveness of routine, every-day care and identifying groups of patients which 
are (un-)likely to benefit from existing interventions. 
 
More recently the real-world evidence principle has been extended to pre-launch clinical testing with 
the phase III Salford Lung Study.54 The move towards earlier real-world evidence generation requires 
early engagement with Health Technology Assessment authorities to understand the potential cost-
effectiveness of the intervention, allowing industry to invest in appropriate evidence generation 
accordingly. 
 
Particular challenges surround the assessment of complex interventions, such as integrated care, and 
patients with complex needs, such as triple therapy in chronic obstructive pulmonary disease,55 
different sequences of disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients56 and 
patients with multiple and potentially interacting co-morbidities. In the latter case, there is evidence to 
suggest some combinations of conditions increase overall costs, while others decrease overall costs due, 
for instance, to overlapping treatments.57 Consequently cost-effectiveness evaluations for individual 
interventions cannot be considered “additively” but need to be assessed in context. A methodological 
framework for “Whole Disease Modeling” has been developed by Tappenden et al., which considers all 
treatments and diagnostics along the pathway of care for a simulated cohort,58 but the only examples 
that we could find of this method being used were with colorectal cancer and depression.59,60 
  
 
 
 
 
Multi-morbidity also has implications for quality of life outcome measures which, like costs, do not 
behave additively over conditions.61  Outcome measures are also problematic in particular patient 
groups, such as those with impaired cognitive abilities who may not be able to complete patient 
reported outcome measures;62  and in particular interventions, such as palliative care, where the choice 
of outcome is not straightforward or uniform.63 The latter point extends to the “care sector” generally, 
where fewer appropriate outcome tools are available than in the “cure sector”, although recent 
research such as the Adult Social Care Outcomes Toolkit (ASCOT) has started to address this.64 
Consequently there is an issue of benefit measurement in complex treatment situations and patient 
profiles. Similarly, indirect costs derived from lost productivity are likely to underestimate the economic 
burden of conditions affecting older people, where indirect costs are associated with informal care65 and 
with loss of economically meaningful activities such as volunteering and child care. 
Earlier recommendations have called for resource use and unit costs to be reported separately,66,67 and 
the present panel re-iterates this recommendation to facilitate transferability of economic evidence 
across settings. Transferability and validity may be further enhanced through development of 
standardized, open-source and open-access economic models that are intended to appropriately reflect 
disease progression and provide unbiased estimates of cost-effectiveness, subject to contextualized 
input parameters. The re-use and customization of economic models is commonplace for commercial 
models, such as the CORE Diabetes model68 which is cited in numerous analyses, but transparent and 
validated models in the public domain would be a valuable resource for researchers and reimbursement 
agencies alike, reducing duplication of effort in economic components of reimbursement submissions 
across countries along the same principle as the EUNetHTA approach for HTA.69 Here, there is scope for 
greater use and further development of standardized approaches such as the Gates Reference Case70 
and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS).71 
 
Finally the panel recognized the limited cross-talk between health economic evaluation, largely cost- 
effectiveness, and economic evaluations in other sectors, often cost-benefit. A recent review found 
health effects were more likely to be considered in economic evaluations if there was a direct link to 
health and lives saved, such as road traffic safety, but less likely if health was indirectly affected e.g. 
through social determinants.72 Quantification of health impacts of non-health policies such as education, 
work force policies, environment and urban planning could help to bridge this gap. 
 
In conclusion, the panel suggests a research agenda for health economics which includes understanding 
of the strengths and weaknesses of real-world evidence for the assessment of new and existing health 
care interventions, uses economic insights to identify patient groups that are most likely to benefit 
from care and to guide investment and disinvestment decisions accordingly. This includes the 
assessment of complex, sequential and multi-morbid care. Appropriate methods are needed for 
capturing costs and outcomes accurately, particularly with more challenging interventions and patient 
groups, and for encouraging the uptake of health outcomes in economic evaluations outside the health 
sector. The panel also noted the large proportions of economics analyses that come from vested 
interests such as pharmaceutical manufacturers and the associated risk of bias. Transparency about 
funding and other conflicts of interest and commitment from authors to publish full details of methods, 
inputs and results was considered important, as was the need for publication of independent analyses. 
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Rank # 1990 2010 
1 Ischemic Heart Disease Ischemic Heart Disease 
2 Stroke Low Back Pain 
3 Low Back Pain Stroke 
4 Lung Cancer Major Depressive Disorder 
5 Road Injury Lung Cancer 
6 Major Depressive Disorder Falls 
7 COPD COPD 
8 Falls Diabetes 
9 Diabetes Other  MusculoskeletalI 
10 Self-harm Neck pain 
I 
“Other Musculoskeletal disorders is a residual category of 62 discrete conditions including 
arthropathies, systemic connective tissue disorders, dorsopathies, soft tissue disorders, osteopathies, 
chondropathies and “Other disorders of the musculoskeletal system and connective tissue” (web 
table 3 of Lozano et al
69
). 
  
 
 
 
 
 
 
 
GBD 
Rank 
2010 
Condition Literature Mapping 
Screened Included 
 
Total 
reviews 
 
Recent 
reviewsI 
 Literature distribution 
Clinical Intervention with most 
modalitiesII evidenceVII: number of studies (% 
of all studies) 
 
1 Ischemic heart disease 1,818 232 49 7 30 PCI for angina: 46V (20%) 
2 Low back pain 190 64 12 5 63 Physical therapy: 20 (31%) 
3 Stroke 461 116 20 9 52 Atrial fibrillation: 39 (34%) 
4 Major depressive 
disorder 
151 61 3 2 14 Pharmacology: 35 (57%) 
5 Lung cancerIII 686 49 31VI 6 25 Erlotinib, gefitinib or afatinib in 
EGFR mutation cancer: 14 (29%) 
6 Falls 180 42 3 2 14 Exercise: 16 (38%) 
7 Chronic obstructive 
pulmonary disorder 
267 68 11 4 58 LAMA, LABA: 20 (29%) 
8 Diabetes type 1+2 1,208 242 77 25 28 Insulin: 28 (12%) 
9 Osteoporosis IV 352 71 11 5 12 Bisphosphonates: 34 (48%) 
OsteoarthritisIV 248 34 8 4 21 NSAIDs: 16 (47%) 
10 Neck pain 35 15 2 2 24 Spinal manipulation: 9 (60%) 
 
I  2009 or later 
II Number of clinical management strategies identified through clinical guidelines and expert opinion 
III NSCLC 
IV Osteoporosis is selected as a condition of particular importance out of the 62 discrete conditions comprising the “Other Musculoskeletal 
Disorder” category, which ranks 9th in the GBD. Osteoarthritis, being the most significant single MSD in terms of burden of disease, was included 
to complement the “Other Musculoskeletal Disorder” category 
VStable (46) plus unstable (19) ischemic heart disease patients 
VI for Small Cell Lung Cancer and Non-Small Cell Lung Cancer 
VIIEconomic studies are categorized according to all comparators included 
PCI = Percutaneous Coronary Intervention; LAMA = Long Acting Muscarinic Antagonists; LABA = Long Acting Beta2 Agonists; EGFR = Epidermal 
Growth Factor Receptor 
 
 
 
 
 
